Eli Lilly & Co

Eli Lilly & Co

LLYยท Manufacturingยท Fiscal year ends in December

CEO pay in FY2025

David A. Ricks is the CEO of Eli Lilly & Co and was paid $36.7M in FY2025 (Dec), up 25%.

PayNo stock prices for these years
CEO pay is from each Eli Lilly & Co proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1David A. RicksFY2025
  2. 2Daniel M. Skovronsky, M.D., Ph.D.FY2025
  3. 3Anat HakimFY2025
  4. 4Lucas MontarceFY2025
  5. 5Jake Van NaardenFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Eli Lilly & Co paid its 5 named executives $80.4M in total in FY2025 (Dec). CEO David A. Ricks was paid $36.7M of that.

Name
David A. RicksChair, President, and Chief Executive Officer
Daniel M. Skovronsky, M.D., Ph.D.Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
Anat HakimExecutive Vice President, General Counsel and Secretary
Lucas MontarceExecutive Vice President and Chief Financial OfficerNot disclosed
Jake Van NaardenExecutive Vice President and President, Lilly Oncology and Head of Corporate Business Development

of each named executive, from the Summary Compensation Table of each proxy.

Peers15

See all

The FY2024 (Dec) proxy of Eli Lilly & Co names 15 peer companies for pay. Among Eli Lilly & Co and these peers, CEO pay was the highest of 7 and total shareholder return was the highest of 7.

1st highest of 7in Eli Lilly & Co and its pay peers, FY2024 (Dec) by CEO pay:

$18.5M$29.2M

1st highest of 7in Eli Lilly & Co and its pay peers, FY2024 (Dec) by total shareholder return:

$52$627

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

No new filings about this company in the feed.

Filings23

See all
Current report8-KMay 7, 2026โ€”
Proxy statementDEF 14AMar 20, 2026FY2025
Annual report10-KFeb 12, 2026FY2025
Current report8-KNov 21, 2025โ€”
Current report8-KMay 8, 2025โ€”
Proxy statementDEF 14AMar 21, 2025FY2024